Navigation Links
First Time Federal Funding for Mesothelioma Research
Date:1/23/2008

Department of Defense Lists Asbestos-Related Cancer For Medical Research

Projects

SANTA BARBARA, Calif., Jan. 23 /PRNewswire-USNewswire/ -- The Department of Defense (DoD) Peer Reviewed Medical Research Program was appropriated $50 million in the Defense Appropriations Bill that the President signed in mid- November. The Mesothelioma Applied Research Foundation (Meso Foundation) is excited to announce that, for the first time, mesothelioma will be included as a research priority within the DoD's Medical Research Program, to begin February 2008. As a candidate research area within the program, mesothelioma investigators are eligible to compete for funding through the program's 2008 grant cycle.

"The Meso Foundation has been working with fifteen senators, led by Senator Max Baucus (D-MT), advocating the federal government to respond to the mesothelioma crisis through a commitment of new federal research dollars," said Chris Hahn, Executive Director of The Meso Foundation. "Our advocacy efforts in this area for the past several years finally paid off."

Federal medical research projects must be of clear scientific merit and have direct relevance to military health. Military relevance is a key feature of the Investigator-Initiated award, a connection that will not be difficult for mesothelioma researchers to establish for their grant applications.

There is a long history of asbestos exposure in military service, and a significant elevated risk of mesothelioma in the military population. In fact, approximately one third of mesothelioma cases have been shown to involve Navy and shipyard exposures. Given the long latency of the disease, even if exposures are reduced, mesothelioma will continue to affect the veteran and military population for decades to come.

This funding opportunity can serve as a vital resource to the meso community and is another crucial step toward advancing the research and tre
'/>"/>

SOURCE Meso Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Coherent, Inc. to Webcast First Fiscal Quarter 2008 Results
2. Boston IVF is First in Northeast to Offer Pioneering Test of Womens Biological Clock
3. Moog Inc. Announces First Quarter 2008 Earnings Webcast on January 25, 2008
4. QLT reduces workforce as first step in its strategic restructure
5. Immunosyn Announces the Successful Completion of First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
6. UNC, Duke lead first statewide shaken baby prevention research project in US
7. New Research Shows Nutrition Programs Targeting Pregnancy and First 24 Months of Life Dramatically Improve Child Survival and Overall Health
8. The First Annual LOVE L.A. Show Promotes Sensuality, Relationships and Sexual Education
9. First in Nation: notMYkid Educational Center Is Now a Reality Thanks to a Partnership Between Chrysler, Barrett-Jackson and notMYkid
10. Kim & Scotts Gourmet Pretzels(R) Introduces Its First Empowered Pretzel(TM) Available Online and to Wholesale
11. First rigorous analysis defines impact of Medicare Part D
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 2Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 3Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 4Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 5Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 6Health News:Buffalo Personal Injury Lawyers Cellino & Barnes Donate $1M to UB School of Law, Appear on Cover of School's Philanthropy Magazine 2Health News:Wellness Manufacturer Wins Two 2009 American Spa Awards 2Health News:The Flag Company, Inc.'s Recently Released “Feel Good” Light Lenses Grows Into Its Own Website 2Health News:The Flag Company, Inc.'s Recently Released “Feel Good” Light Lenses Grows Into Its Own Website 3Health News:NVHR Offers Congressman Hank Johnson Support & Encouragement as He Battles Chronic Hepatitis C Virus 2
Breaking Medicine Technology:ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 3ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 5ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 6ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 7FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Mathematical modeling predicts response to Herceptin 52980 1Mathematical modeling predicts response to Herceptin 52980 2Ongoing Study Shows That Endovascular Therapy is Associated With High Cure Rate for Childhood Eye Cancer 52979 1Ongoing Study Shows That Endovascular Therapy is Associated With High Cure Rate for Childhood Eye Cancer 52979 2Ongoing Study Shows That Endovascular Therapy is Associated With High Cure Rate for Childhood Eye Cancer 52979 3Ongoing Study Shows That Endovascular Therapy is Associated With High Cure Rate for Childhood Eye Cancer 52979 4The CLASS Act 3A Retirement In Security 52977 1The CLASS Act 3A Retirement In Security 52977 2